Teleflex Celebrates 175,000 Patients Treated with the UroLift® System
March 11 2020 - 6:45AM
Teleflex Incorporated (NYSE: TFX) today announced that 175,000
patients have now been treated globally* with its minimally
invasive UroLift® System—a safe and effective treatment for
Benign Prostatic Hyperplasia (BPH) that provides rapid symptom
relief and improved quality of life, while preserving sexual
function.**1,3
BPH, also known as enlarged prostate, is a
non-cancerous enlargement of the prostate that occurs as men age.
This common condition is marked by bothersome urinary symptoms,
such as getting up frequently at night to urinate, that can lead to
loss of productivity, depression, and decreased quality of life.4
BPH affects over 40 million men in the United States alone.5 If
left untreated, the condition can worsen over time and cause
permanent bladder damage.6
“We are gratified that physicians have entrusted
the UroLift System as a treatment for 175,000 patients around the
world—a testament to the demand for our proven option that may
allow men to stop taking daily medication and avoid major surgery,”
said Dave Amerson, president of the Teleflex Interventional Urology
business unit. “We are pleased that growing numbers of physicians
continue to adopt the UroLift System as a standard of care
treatment that offers patients an effective and durable BPH
solution while preserving sexual function.”1,3
The Prostatic Urethral Lift (using the UroLift
System) is recommended for the treatment of BPH in both the
American Urological Association and European Association of Urology
clinical guidelines. In addition to the United States and Europe,
the treatment is available in Canada, Australia, New Zealand,
Mexico, South Korea, Japan, Singapore, Hong Kong, and Chile.
“I have long believed that this innovative
treatment would be a game-changer for the field of urology and for
men suffering from enlarged prostate symptoms,” said Steven Gange,
M.D., F.A.C.S.. “The robust clinical evidence supporting the
UroLift System as a safe and effective treatment option provides
urologists with confidence they are providing patients a procedure
that offers rapid symptom relief and recovery1. The UroLift System
is the only BPH procedure shown to not cause new onset, sustained
erectile or ejaculatory dysfunction1,3,7,8 and allows men to return
to their normal routines with minimal downtime.”1
About the
UroLift® SystemThe FDA-cleared UroLift System is a
proven, minimally invasive technology for treating lower urinary
tract symptoms due to benign prostatic hyperplasia (BPH). The
UroLift permanent implants, delivered during a minimally invasive
transurethral outpatient procedure, relieve prostate obstruction
and open the urethra directly without cutting, heating, or removing
prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged
prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function.**1,3 Patients also experienced significant
improvement in quality of life. Most common adverse events reported
include hematuria, dysuria, micturition urgency, pelvic pain, and
urge incontinence. Most symptoms were mild to moderate in severity
and resolved within two to four weeks after the procedure. The
Prostatic Urethral Lift procedure using the UroLift System is
recommended for the treatment of BPH in both the American
Urological Association and European Association of Urology clinical
guidelines. The UroLift System is available in many markets
worldwide. Over 175,000* men have been treated with the UroLift
System. Learn more at www.UroLift.com.
About Teleflex Interventional
UrologyThe Teleflex Interventional Urology Business Unit
is dedicated to developing innovative, minimally invasive and
clinically effective devices that address unmet needs in the field
of urology. Our focus is on improving the standard of care for
patients with BPH using the UroLift System, a minimally invasive
permanent implant system that treats symptoms while preserving
sexual function.**3,4 Learn more at www.NeoTract.com.
About Teleflex
IncorporatedTeleflex is a global provider of medical
technologies designed to improve the health and quality of people’s
lives. We apply purpose driven innovation – a relentless pursuit of
identifying unmet clinical needs – to benefit patients and
healthcare providers. Our portfolio is diverse, with solutions in
the fields of vascular and interventional access, surgical,
anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®,
Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® –
trusted brands united by a common sense of purpose.
Dr. Steven Gange is a paid consultant of
NeoTract l Teleflex.
*Management estimate based on product sales
and average units per procedure
**No instances of new, sustained erectile or
ejaculatory dysfunction.
Contacts:For Teleflex
Incorporated: Jake Elguicze, 610.948.2836 Treasurer and Vice
President, Investor Relations Media: Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com
MAC01292-01 Rev A
____________________*Management
estimate based on product sales and average units per
procedure**No instances of new, sustained erectile or ejaculatory
dysfunction1Roehrborn J Urol 2013 LIFT Study2 Roehrborn, Can J Urol
20153McVary, J Sex Med 20164 Speakman et al. 2014 BJUI
International5 NeoTract US Market Model estimates for 2018 based on
IQVIA Health Drug and Procedure data6 Tubaro et al. 2003 Drugs
Aging7AUA BPH Guidelines 2003, 2010, 20188 Naspro, Eur Urol 2009;
4. Montorsi, J Urol 20089Sonksen EU Urol 2015 10Roerhborn et
al. Can J Urol 2017
Teleflex (NYSE:TFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Sep 2023 to Sep 2024